Announced the new medium-term management plan “Transformation 2030.” Aims for net sales of 70 hundred million yen or more and ordinary income of 20 hundred million yen or more in FY2030 through expansion of the CRO business and monetization of the TR business. Will strengthen DX\/AX initiatives and globalization, pursuing sustainable growth anchored by four growth engines.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2395","jir_company_name":"Shin Nippon Biomedical Laboratories, Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2395-20261110-03.pdf","jir_short_summary":"Announced the new medium-term management plan \"Transformation 2030.\" Aims for net sales of 70 hundred million yen or more and ordinary income of 20 hundred million yen or more in FY2030 through expansion of the CRO business and monetization of the TR business. Will strengthen DX\/AX initiatives and globalization, pursuing sustainable growth anchored by four growth engines.","jir_summary":"### Overview of Transformation 2030\nThe new medium-term management plan \"Transformation 2030\" was presented, setting financial targets of net sales of 70 hundred million yen or more, ordinary income of 20 hundred million yen or more, and ROE\/ROIC of 10% or more. Centered on DX\/AX promotion and globalization, the plan strengthens the revenue structures of the CRO and TR businesses and positions four growth engines\u2014nonclinical\/clinical CRO, TR business, DX\/AX, and globalization\u2014as pillars for expansion.\n\n### Growth Engines and Business Structure\nTransformation 2030 will drive mid-term growth through four growth engines. The first engine is achieving a dominant CRO position; the second is commercialization and monetization of the TR business; the third is promotion of DX\/AX and globalization; and the fourth is deepening new domains and business collaborations. Through these, the company intends to build and expand revenue streams across both CRO and TR.","jir_financial_highlights":"Net Sales: 70 hundred million yen or more (FY2030 target)\nOrdinary Income: 20 hundred million yen or more (FY2030 target)\nROE: 10% or more (FY2030 target)\nROIC: 10% or more (FY2030 target)","jir_category":"","jir_hashtags":"#ShinNipponBiomedicalLaboratoriesLtd #Transformation2030 #MediumTermManagementPlan","jir_key_figures":"Net Sales: 70 hundred million yen or more (FY2030 target)\nOrdinary Income: 20 hundred million yen or more (FY2030 target)\nROE: 10% or more (FY2030 target)","jir_meta_title":"Shin Nippon Biomedical Laboratories, Ltd. \u2014 Transformation 2030: New Medium-Term Plan Targeting CRO and TR Monetization","jir_meta_description":"Analysis of Shin Nippon Biomedical Laboratories, Ltd.'s new medium-term management plan \"Transformation 2030.\" Details the strategy to achieve net sales of 70 hundred million yen or more and ordinary income of 20 hundred million yen or more by FY2030 through CRO\/TR expansion, DX\/AX promotion, and globalization.","jir_og_title":"Shin Nippon Biomedical Laboratories, Ltd. | Overview and Growth Strategy of Transformation 2030","jir_og_description":"Transformation 2030 centers on monetizing CRO and TR businesses while advancing DX\/AX and globalization, and discloses FY2030 financial targets.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":17048,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-145947","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n